Plasma Exchange to Treat Cytokine Release Syndrome and Immune Effector Cell-Associated Neurotoxicity Syndrome after Anti-CD19 Chimeric Antigen Receptor-T Cell Infusion: A Case Report
Journal Title: Diseases & Research - Year 2021, Vol 1, Issue 1
Abstract
Adoptive cell immunotherapy with chimeric antigen receptor-T (CAR-T) cells has shown remarkable clinical out-comes. However, cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) are the two most significant toxicities during this therapy and can be life-threatening. We described a 12-year-old juvenile who had been diagnosed with relapsed and refractory B-cell acute lymphocytic leukemia (r/r B-ALL). The patient was recruited into our phase I clinical trial concerning ssCAR-T-19 (anti-CD19 CAR-T cells with shRNA targeting IL-6), and 5*106/kg of engineered ssCAR-T-19 cells were administered. After infusion, the patient underwent a typical CRS reaction, with fever and increased cy-tokine levels. He was treated with antipyretic drugs, methylprednisolone, and tocilizumab, but the effect was limited. He devel-oped coagulation abnormalities, multiple organ dysfunction, lung infection and ICANS. Apart from the necessary supportive and symptomatic treatment, plasma exchange was performed three times in four days while methylprednisolone pulse was performed for two consecutive days. After that, the body temperature, heart rate, and especially the cytokine levels declined. But digestive tract hemorrhage occurred to him and he was transferred to intensive care unit. To make things worse, he developed acute re-spiratory failure and received intubation and mechanical ventilation. In addition, symptomatic treatment such as suppression of stomach acid and anti-infection was given. The bleeding was controlled, and his respiratory function improved, and the CRS and ICANS-related symptoms were relieved. He received extubation and was transferred back to the general ward. Additionally, a bone marrow smear showed no lymphoblast cells, and minimal residual disease in bone marrow was negative on day +22 and day +30. The patient was eventually discharged in a normal condition. In conclusion, CRS and ICANS as two most common toxici-ties after CAR-T therapy, which often cause patient death. Several methods such as anti-IL-6 therapy and/or corticosteroids have been adopted in the management guidelines of CRS and ICANS except plasma exchange. This case shows the validity of plasma exchange in a patient with severe CRS and ICANS after receiving ssCAR-T.
Authors and Affiliations
Yan Qiu, Wen-Jie Gong, Li-Qing Kang, Ai-Ning Sun, De-Pei Wu, Lei Yu, Jian Zhang, Sheng-Li Xue
Keywords
Related Articles
- EP ID EP740192
- DOI 10.54457/DR.202101005
- Views 57
- Downloads 2
Recurrent Middle Ear Cancer: Case Report
Background: Middle ear cancer is clinically uncommon, representing approximately 1.5% of ear malignancies and 0.03% to 0.06% of all cancers. Recurrent cases of middle ear cancer are particularly rare. This report discuss...
Pulmonary Mucosa-Associated Lymphoid Tissue Lymphoma: A Report of 2 Cases and Literature Review
Pulmonary mucosa-associated lymphoid tissue (MALT) lymphoma is indolent and progresses more slowly than other malignant lymphomas. The clinical features are not specific and the diagnosis can often be difficult. Here, we...
Significance of Liquid Biopsy Containing Circulating Tumor DNA (ctDNA) Analysis for Evaluation and Management of Metastatic Cancer
According to the GLOBOCAN 2020 data from WHO, nearly 10 million deaths took place due to cancer thus, cancer became a leading cause of death all over the world. The most common cancer are breast cancer, lung cancer, colo...
Dendritic Cell Subsets: The Next Target for Pregnant Complications?
Dendritic cells (DCs) are professional antigen-presenting cells with both immune stimulatory and regulatory functions. DCs are critical players in pregnancy, whose dysregulation is associated with multiple pregnancy-rela...
Multiparameter Flow Cytometry: An Important Auxiliary Tool for The Diagnosis and Differential Diagnosis of Myelodysplastic Neoplasms
Multiparameter flow cytometry (MFC) shows promise in the diagnosis and differential diagnosis of myelodysplastic neoplasms (MDS). By identifying abnormal immunophenotypes of different cell lineages in bone marrow (BM) ce...